Table 7 Resolution of comorbidities in the total and propensity score-matched cohorts.
Total cohort | Matched cohort | |||||||
|---|---|---|---|---|---|---|---|---|
SPSG + RPSG (n = 75) | CLSG (n = 73) | Total (n = 148) | P-value | SPSG + RPSG (n = 50) | CLSG (n = 50) | Total (n = 100) | P-value | |
Hypertension [n, (%)] | 0.809 | 0.687 | ||||||
Remission, complete | 10 (25.0) | 13 (28.3) | 23 (26.7) | 10 (41.7) | 11 (34.4) | 21 (37.5) | ||
Remission, partial | 15 (37.5) | 13 (28.3) | 28 (32.6) | 5 (20.8) | 10 (31.3) | 15 (26.8) | ||
Improvement | 12 (30.0) | 17 (37.0) | 29 (33.7) | 7 (29.2) | 10 (31.3) | 17 (30.4) | ||
Unchanged | 3 (7.5) | 3 (6.5) | 6 (7.0) | 2 (8.3) | 1 (3.1) | 3 (5.4) | ||
Diabetes [n, (%)] | 0.826 | 0.859 | ||||||
Remission, complete | 15 (68.2) | 17 (60.7) | 32 (64.0) | 7 (58.3) | 13 (65.0) | 20 (62.5) | ||
Remission, partial | 2 (9.1) | 2 (7.1) | 4 (8.0) | 1 (8.3) | 2 (10.0) | 3 (9.4) | ||
Improvement | 4 (18.2) | 8 (28.6) | 12 (24.0) | 4 (33.3) | 5 (25.0) | 9 (28.1) | ||
Unchanged | 1 (4.5) | 1 (3.6) | 2 (4.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Dyslipidemia [n, (%)] | 0.018 | 0.180 | ||||||
Remission | 17 (37.0) | 28 (63.6) | 45 (50.0) | 12 (42.9) | 18 (64.3) | 30 (53.6) | ||
Improvement | 25 (54.3) | 14 (31.8) | 39 (43.3) | 16 (57.1) | 10 (35.7) | 26 (46.4) | ||
Unchanged | 4 (8.7) | 1 (2.3) | 5 (5.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Aggravated | 0 (0.0) | 1 (2.3) | 1 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
GERD [n, (%)] | ||||||||
Resolution | ||||||||
Symptoms only | 3 (4.0) | 1 (1.4) | 4 (2.7) | 0.620 | 2 (4.0) | 1 (2.0) | 3 (3.0) | 0.999 |
Esophagitis on endoscopy | 5 (6.7) | 1 (1.4) | 6 (4.1) | 0.209 | 5 (10.0) | 1 (2.0) | 6 (6.0) | 0.204 |
De novo diagnosis | ||||||||
Symptoms only | 13 (17.3) | 24 (32.9) | 37 (25.0) | 0.029 | 8 (16.0) | 15 (30.0) | 23 (23.0) | 0.096 |
Esophagitis on endoscopy | 9 (13.4) | 16 (24.6) | 25 (18.9) | 0.101 | 4 (8.5) | 12 (26.1) | 16 (17.2) | 0.025 |
